Artificial intelligence–guided precision treatment of chronic kidney disease–mineral bone disorder

Adam E. Gaweda, Eleanor D. Lederer, Michael E. Brier

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic kidney disease (CKD)–mineral bone disorder (MBD) is a complex clinical syndrome that begins early during CKD and evolves into one of the deadliest complications of CKD through its effects on the cardiovascular and skeletal systems. Achievement of treatment goals to decrease the risk of accelerated cardiovascular events and fractures has been challenging. We hypothesized that application of quantitative systems pharmacology (QSP) modeling combined with artificial intelligence techniques could improve the management of CKD–MBD with the goal of improving outcomes for patients with CKD. We present the implementation of a reinforcement learning (RL) approach to achieve the prescribed goals for serum calcium, phosphorus, and parathyroid hormone through concurrent dosing of phosphate binders, vitamin D analogs, and calcimimetics by simulation in 80 subjects in Matlab. In silico simulation results demonstrate that the application of a QSP model coupled with RL more effectively and quickly achieves treatment goals even in the setting of inferior simulated subject compliance with medical therapy and identifies key decision variables for therapeutic recommendations.

Original languageEnglish (US)
JournalCPT: Pharmacometrics and Systems Pharmacology
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Modeling and Simulation
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Artificial intelligence–guided precision treatment of chronic kidney disease–mineral bone disorder'. Together they form a unique fingerprint.

Cite this